// App-Quantinova.ai

: Achieving Therapeutic Anti-Xa Levels Using Rivaroxaban for Venous Thromboembolism in a Morbidly Obese Patient with a BMI >70

Researchers

Presenter

  • Swathi Prakash

Principal Investigators

  • Kingsley Dah

  • Sayed Ghafouri

  • Alan De La Rosa

  • Mateo Porres-Aguilar

Medical Centers

  • Department of Hematology Oncology, Texas Tech University Health Sciences Center Lubbock, Lubbock, TX

  • Department of Internal Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Cardiovascular (CVS)

  • Pulmonary/Respiratory Diseases

Disease

  • Venous thrombosis

  • Pulmonary embolism

  • Dyspnea

Biomarkers

  • Body mass index

Drug/Treatment

  • rivaroxaban

  • Hydroxyzine

  • Heparin

Outcome

  • N/A

Study Design

  • Efficacy

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved